{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:46:06Z","timestamp":1791859566305,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2026,10]]},"abstract":"Abstract<\/jats:title>\n \n Introduction<\/jats:title>\n Candida bloodstream infections remain a significant complication of malignancies and their therapies.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n \n To investigate the epidemiology of\n Candida<\/jats:italic>\n species causing bloodstream infections in patients with malignancies.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We retrospectively reviewed bloodstream infections due to\n Candida<\/jats:italic>\n from July 2008 to June 2023 in patients admitted under hematological, solid tumor and surgical services. Common species included\n C. albicans, Nakaseomyces glabratus<\/jats:italic>\n (formerly\n C. glabrata<\/jats:italic>\n ),\n Pichia kudriavzevii<\/jats:italic>\n (formerly\n C. krusei<\/jats:italic>\n )\n , C. parapsilosis<\/jats:italic>\n complex and\n C. tropicalis<\/jats:italic>\n . The rest were classified as uncommon.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Incidence of candidemia was 0.46 episodes per 1,000 patients-days of admission. Of 265 episodes of candidemia, 102 (38.5%) occurred in patients under hematological services, 59 (22.3%) under solid tumor and 104 (39.2%) under surgical services. Among 271 available isolates,\n C. albicans<\/jats:italic>\n was the predominant species, accounting for 96 (35.4%).\n N. glabratus<\/jats:italic>\n (formerly\n C. glabrata<\/jats:italic>\n ) was the dominant species in 15 (55.6%) episodes of candidemia following triazole exposure (\n p<\/jats:italic>\n : 0.008) and\n C. parapsilosis<\/jats:italic>\n the dominant in 15 (34.9%) following echinocandin exposure (\n p<\/jats:italic>\n :\u2009<\u2009.001). Candidemia due to uncommon\n Candida<\/jats:italic>\n species occurred in 22 (8.3%) episodes for the total cohort and in 17 (16.7%) in patients with hematological malignancies (\n p<\/jats:italic>\n :\u2009<\u2009.001). Multivariable logistic regression analysis identified neutropenia (OR 4.5 [95% CI 1.7\u201311.9]) as independent predictor of candidemia caused by uncommon species.\n <\/jats:p>\n <\/jats:sec>\n \n Conslusion<\/jats:title>\n Candidemia due to uncommon species occurred with higher frequency in patients with malignancies, with the highest rates observed among those with hematological malignancies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s11046-026-01088-z","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:24:27Z","timestamp":1788351867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and Species Distribution of Candida Bloodstream Infections in a Comprehensive Cancer Center, 2008\u20132023"],"prefix":"10.1007","volume":"191","author":[{"given":"Mohammad","family":"El-Atoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahm H.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bonnewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Almyroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1088_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2001","unstructured":"Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2001;50:1091\u2013100.","journal-title":"Clin Infect Dis"},{"key":"1088_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.diagmicrobio.2012.10.003","volume":"74","author":"M Pfaller","year":"2004","unstructured":"Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis. 2004;74:323\u201331.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1088_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1086\/321811","volume":"33","author":"HM Blumberg","year":"2001","unstructured":"Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177\u201386.","journal-title":"Clin Infect Dis"},{"key":"1088_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0732-8893(93)90020-8","volume":"17","author":"J Berenguer","year":"1993","unstructured":"Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17:103\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1088_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/cid\/cis200","volume":"54","author":"MH Nguyen","year":"2012","unstructured":"Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240\u20138.","journal-title":"Clin Infect Dis"},{"key":"1088_CR6","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1128\/JCM.00609-11","volume":"49","author":"CD Pfeiffer","year":"2011","unstructured":"Pfeiffer CD, Samsa GP, Schell WA, et al. Quantitation of Candida CFU in initial positive blood cultures. J Clin Microbiol. 2011;49:2879\u201383.","journal-title":"J Clin Microbiol"},{"key":"1088_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:409\u201317.","journal-title":"Clin Infect Dis"},{"key":"1088_CR8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/infdis\/jiaa502","volume":"223","author":"EE Ricotta","year":"2021","unstructured":"Ricotta EE, Lai YL, Babiker A, et al. Invasive candidiasis species distribution and trends, United States, 2009\u20132017. J Infect Dis. 2021;223:1295\u2013302.","journal-title":"J Infect Dis"},{"key":"1088_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348\u201359.","journal-title":"N Engl J Med"},{"key":"1088_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335\u201347.","journal-title":"N Engl J Med"},{"key":"1088_CR11","doi-asserted-by":"publisher","first-page":"e70136","DOI":"10.1111\/myc.70136","volume":"68","author":"M El-Atoum","year":"2025","unstructured":"El-Atoum M, Chen GL, Bonnewell JP, et al. Incidence rates of Candida bloodstream infections in patients with malignancies in a comprehensive cancer centre. Mycoses. 2025;68:e70136.","journal-title":"Mycoses"},{"key":"1088_CR12","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","volume":"6","author":"MA Pfaller","year":"2019","unstructured":"Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016. Open Forum Infect Dis. 2019;6:S79\u201394.","journal-title":"Open Forum Infect Dis"},{"key":"1088_CR13","doi-asserted-by":"publisher","first-page":"iv48","DOI":"10.1093\/jac\/dkz287","volume":"74","author":"J Fuller","year":"2011","unstructured":"Fuller J, Dingle TC, Bull A, et al. Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011-16 study. J Antimicrob Chemother. 2011;74:iv48\u201354.","journal-title":"J Antimicrob Chemother"},{"key":"1088_CR14","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/cncr.23466","volume":"112","author":"R Hachem","year":"2008","unstructured":"Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493\u20139.","journal-title":"Cancer"},{"key":"1088_CR15","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1002\/cncr.24507","volume":"115","author":"NV Sipsas","year":"2009","unstructured":"Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745\u201352.","journal-title":"Cancer"},{"key":"1088_CR16","first-page":"1833","volume":"20","author":"D Farmakiotis","year":"1833","unstructured":"Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis. 1833;20:1833\u201340.","journal-title":"Emerg Infect Dis"},{"key":"1088_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad056","author":"R Nishida","year":"2009","unstructured":"Nishida R, Eriguchi Y, Miyake N, et al. Breakthrough candidemia with hematological disease: results from a single-center retrospective study in Japan, 2009-2020. Med Mycol. 2009. https:\/\/doi.org\/10.1093\/mmy\/myad056.","journal-title":"Med Mycol"},{"key":"1088_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jinf.2023.08.001","volume":"87","author":"MC Arendrup","year":"2023","unstructured":"Arendrup MC, Arikan-Akdagli S, Jorgensen KM, et al. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: results from the ECMM Candida III study. J Infect. 2023;87:428\u201337.","journal-title":"J Infect"},{"key":"1088_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3109\/13693780903410386","volume":"48","author":"SI Jung","year":"2010","unstructured":"Jung SI, Shin JH, Song JH, et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol. 2010;48:669\u201374.","journal-title":"Med Mycol"},{"key":"1088_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12929-023-00926-2","volume":"30","author":"W Fang","year":"2023","unstructured":"Fang W, Wu J, Cheng M, et al. Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci. 2023;30:42.","journal-title":"J Biomed Sci"},{"key":"1088_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367\u201376.","journal-title":"Clin Infect Dis"},{"key":"1088_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1086\/510677","volume":"44","author":"BH Segal","year":"2007","unstructured":"Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis. 2007;44:402\u20139.","journal-title":"Clin Infect Dis"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-026-01088-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-026-01088-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-026-01088-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:04:28Z","timestamp":1791857068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-026-01088-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1007\/s11046-026-01088-z","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"74"}}